A Multidisciplinary Approach to Standardizing Processes for Blinatumomab Administration.

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Blinatumomab (Blincyto®) is an immunotherapy approved for relapsed or refractory acute lymphoblastic leukemia (ALL).
• Effective administration of novel oncologic therapies requires careful planning and execution.
• Multidisciplinary collaboration is crucial for managing complex cancer treatments.

Purpose of the Study:

• To describe the institutional experience with blinatumomab administration.
• To highlight the importance of a multidisciplinary team in ensuring safe blinatumomab use.
• To provide a model for other centers implementing blinatumomab therapy.

Main Methods:

• Retrospective review of blinatumomab administration protocols.
• Description of the multidisciplinary team structure and responsibilities.
• Focus on collaboration between nursing, pharmacy, prescribers, and support staff.

Main Results:

• A multidisciplinary collaborative approach was identified as essential for safe blinatumomab administration.
• Defined roles and communication pathways facilitated effective management.
• The established framework supported the successful integration of blinatumomab into clinical practice.

Conclusions:

• Multidisciplinary collaboration is key to the safe and effective administration of blinatumomab.
• This collaborative model can be adapted by other institutions treating ALL.
• Successful implementation of blinatumomab relies on coordinated efforts across healthcare disciplines.